...
首页> 外文期刊>ACS Synthetic Biology >Targeted Gene Deletion Using DNA-Free RNA-Guided Cas9 Nuclease Accelerates Adaptation of CHO Cells to Suspension Culture
【24h】

Targeted Gene Deletion Using DNA-Free RNA-Guided Cas9 Nuclease Accelerates Adaptation of CHO Cells to Suspension Culture

机译:使用无DNA RNA指导的Cas9核酸酶的靶向基因缺失加速了CHO细胞对悬浮培养的适应

获取原文
获取原文并翻译 | 示例
           

摘要

Chinese hamster ovary (CHO) cells are the preferred host for the production of a wide array of biopharmaceuticals. Thus, efficient and rational CHO cell line engineering methods have been in high demand to improve quality and productivity. Here, we provide a novel genome engineering platform for increasing desirable phenotypes of CHO cells based upon the integrative protocol of high-throughput RNA sequencing and DNA-free RNA guided Cas9 (CRISPR associated protein9) nuclease-based genome editing. For commercial production of therapeutic proteins, CHO cells have been adapted for suspension culture in serum-free media, which is highly beneficial with respect to productivity and economics. To engineer CHO cells for rapid adaptation to a suspension culture, we exploited strand-specific RNA-seq to identify genes differentially expressed according to their adaptation trajectory in serum-free media. More than 180 million sequencing reads were generated and mapped to the currently available 109,152 scaffolds of the CHO-K1 genome. We identified significantly downregulated genes according to the adaptation trajectory and then verified their effects using the genome editing method. Growth-based screening and targeted amplicon sequencing revealed that the functional deletions of Igfbp4 and AqpI gene accelerate suspension adaptation of CHO-K1 cells. The availability of this strand-specific transcriptome sequencing and DNA-free RNA-guided Cas9 nuclease mediated genome editing facilitates the rational design of the CHO cell genome for efficient production of high quality therapeutic proteins.
机译:中国仓鼠卵巢(CHO)细胞是生产多种生物药物的首选宿主。因此,迫切需要有效和合理的CHO细胞系工程方法来提高质量和生产率。在这里,我们提供了一个新的基因组工程平台,用于基于高通量RNA测序和无DNA导引的Cas9(CRISPR相关蛋白9)核酸酶基于基因组编辑的整合方案,增加CHO细胞的理想表型。为了商业生产治疗性蛋白质,CHO细胞已经适应于在无血清培养基中进行悬浮培养,这在生产率和经济性方面非常有利。为了工程化CHO细胞以快速适应悬浮培养,我们利用链特异性RNA-seq来鉴定根据其在无血清培养基中的适应轨迹差异表达的基因。产生了超过1.8亿个测序读数,并将其定位到CHO-K1基因组的当前可用的109,152个支架上。我们根据适应轨迹确定了明显下调的基因,然后使用基因组编辑方法验证了它们的作用。基于生长的筛选和靶向扩增子测序表明,Igfbp4和AqpI基因的功能性缺失可加速CHO-K1细胞的悬浮适应性。这种链特异性转录组测序和无DNA导引的Cas9核酸酶介导的基因组编辑的可用性促进了CHO细胞基因组的合理设计,以有效地生产高质量的治疗性蛋白质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号